A Case of Anti-Glomerular Basement Membrane Crescentic Glomerulonephritis in a Female Renal Allograft Recipient with Unknown Native Disease: Retrospective Molecular Confirmation of Alport Disease

Mahesha Vankalakunti1, *, Ashish Parekh2, Anil K. B. Thimmegowda3, Rajanna Sreedhara2
1 Manipal Hospitals, Bangalore, India
2 Fortis Hospitals, Bangalore, India
3 BGS Gleneagles Global Hospitals, Bangalore, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 811
Abstract HTML Views: 500
PDF Downloads: 255
ePub Downloads: 242
Total Views/Downloads: 1808
Unique Statistics:

Full-Text HTML Views: 463
Abstract HTML Views: 306
PDF Downloads: 174
ePub Downloads: 149
Total Views/Downloads: 1092

Creative Commons License
© 2019 Mahesha Vankalakunti.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Pathology & Laboratory Medicine #98, Rustom Bagh, HAL Airport Road, Bangalore, INDIA – 560017;
Tel: +91-80-25023564; Fax: +91-80-25254563; Email:


Anti-Glomerular Basement Membrane (anti-GBM) crescentic glomerulonephritis developing in an allograft is a rare phenomenon. A patient with Alport syndrome receiving a renal transplant is at risk of developing anti-GBM glomerulonephritis, due to the absence of normal COL4α3, COL4α4 and COL4α5 trimer of the collagen network. Two unique challenges with planning kidney transplant in such a patient include- ideal donor selection; and risk of developing anti-GBM nephritis. We report a case of post-transplant anti-GBM crescentic glomerulonephritis in a female recipient with unknown native kidney disease who was diagnosed with Alport disease when she presented with hematuria and proteinuria nearly 2 years postrenal transplant. Allograft outcome in our case was unfavourable, patient reaching end-stage kidney disease within 6-month of diagnosis. The patient remains on continuous ambulatory peritoneal dialysis and currently active on the deceased donor transplant waiting list.

Keywords: Alport syndrome, Anti-GBM crescentic glomerulonephritis, Renal transplantation, Proteinuria, Glomerulonephritis, peritoneal dialysis.